A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age
NCT02545543
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
2278
Enrollment
INDUSTRY
Sponsor class
Conditions
Influenza, Human
Interventions
BIOLOGICAL:
Seqirus QIV
BIOLOGICAL:
Comparator QIV
Sponsor
Seqirus